In Feb., a new achievement was reached by Virginia Contract Research Organization Co., Ltd. (VCRO). A biotech company, which was assisted by VCRO, was granted a cell therapy product phase II IND clinical-go for adjuvant immunotherapy from the FDA. The professional, integrated, and local team of VCRO successfully helped customers to achieve the next step of product commercialization.
Congratulation! A cell therapy for adjuvant immunotherapy to treat lung cancer was granted by the US FDA IND!
In Feb., a new achievement was reached by Virginia Contract Research Organization Co., Ltd. (VCRO). A biotech company, which was assisted by VCRO, was granted a cell therapy product phase II IND clinical-go for adjuvant immunotherapy from the FDA. The professional, integrated, and local team of VCRO successfully helped customers to achieve the next step of product commercialization.